Published in J Am Coll Cardiol on January 01, 1997
Troponin: the biomarker of choice for the detection of cardiac injury. CMAJ (2005) 2.23
Cardiac troponins. J Clin Pathol (2004) 0.92
Combined Assessments of Biochemical Markers and ST-Segment Resolution Provide Additional Prognostic Information for Patients With ST-Segment Elevation Myocardial Infarction. Korean Circ J (2011) 0.88
Chapter 4: Other complications of CKD: CVD, medication dosage, patient safety, infections, hospitalizations, and caveats for investigating complications of CKD. Kidney Int Suppl (2011) (2013) 0.86
Cardiac troponins in chest pain can help in risk stratification. BMJ (1999) 0.83
Chapter 5: Referral to specialists and models of care. Kidney Int Suppl (2011) (2013) 0.82
Implications of troponin testing in clinical medicine. Curr Control Trials Cardiovasc Med (2001) 0.81
Cost effectiveness of extended treatment with low molecular weight heparin (dalteparin) in unstable coronary artery disease: results from the FRISC II trial. Heart (2003) 0.80
Diagnostic accuracy of sensitive or high-sensitive troponin on presentation for myocardial infarction: a meta-analysis and systematic review. Vasc Health Risk Manag (2014) 0.79
Long term risk stratification of patients with acute coronary syndromes: characteristics of troponin T testing and continuous ST segment monitoring. Heart (2004) 0.79
Cardiac markers in the early diagnosis and management of patients with acute coronary syndrome. Sultan Qaboos Univ Med J (2009) 0.78
Biomarkers in Acute Coronary Syndrome. Biomark Insights (2008) 0.77
Integrated SPECT/CT for assessment of haemodynamically significant coronary artery lesions in patients with acute coronary syndrome. Eur J Nucl Med Mol Imaging (2011) 0.76
New antithrombotic and antiplatelet treatment. Heart (1999) 0.76
Regular review: treatment possibilities for unstable angina. BMJ (2000) 0.75
Contemporary management of acute coronary syndrome. Postgrad Med J (2005) 0.75
Biochemical advances in detection of the acute coronary syndromes: Implications for therapeutic decisions. Indian J Clin Biochem (1999) 0.75
Debate: Unstable angina - When should we intervene? Curr Control Trials Cardiovasc Med (2000) 0.75
Arterial indications for the low molecular weight heparins. Curr Control Trials Cardiovasc Med (2001) 0.75
Randomised controlled trial of chest pain units is needed. BMJ (2000) 0.75
Predictive value of the novel risk score BETTER (BiomarkErs and compuTed Tomography scorE on Risk stratification) for patients with unstable angina. Herz (2014) 0.75
Eosinophilic inflammation in asthma. N Engl J Med (1990) 8.05
Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet (1999) 4.36
Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med (2000) 4.35
Bronchoalveolar eosinophilia during allergen-induced late asthmatic reactions. Am Rev Respir Dis (1985) 3.77
Relation between troponin T and the risk of subsequent cardiac events in unstable coronary artery disease. The FRISC study group. Circulation (1996) 2.91
Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost (2011) 2.87
Mechanisms behind the prognostic value of troponin T in unstable coronary artery disease: a FRISC II substudy. J Am Coll Cardiol (2001) 2.87
Association of revascularisation with low mortality in non-ST elevation acute coronary syndrome, a report from GUSTO IV-ACS. Eur Heart J (2004) 2.67
Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. Circulation (1997) 2.43
Mechanism of membrane damage mediated by human eosinophil cationic protein. Nature (1986) 2.41
Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. JAMA (2001) 2.37
Cationic proteins of human granulocytes. II. Separation of the cationic proteins of the granules of leukemic myeloid cells. Blood (1974) 2.22
Lipocalins as biochemical markers of disease. Biochim Biophys Acta (2000) 2.08
Cytokine-regulated accumulation of eosinophils in inflammatory disease. Allergy (2004) 2.03
Is early invasive treatment of unstable coronary artery disease equally effective for both women and men? FRISC II Study Group Investigators. J Am Coll Cardiol (2001) 1.92
Early statin treatment following acute myocardial infarction and 1-year survival. JAMA (2001) 1.89
Monoclonal antibodies distinguish between storage and secreted forms of eosinophil cationic protein. Nature (1984) 1.75
The impact of an end-point committee in a large multicentre, randomized, placebo-controlled clinical trial: results with and without the end-point committee's final decision on end-points. Eur Heart J (1999) 1.72
Neutrophil granule proteins in bronchoalveolar lavage fluid from subjects with subclinical emphysema. Am J Respir Crit Care Med (1999) 1.69
Radioimmunoassay of human eosinophil cationic protein. Br J Haematol (1977) 1.68
Influence of allergen avoidance at high altitude on serum markers of eosinophil activation in children with allergic asthma. Clin Exp Allergy (1993) 1.65
Risk stratification in unstable coronary artery disease. Additive value of troponin T determinations and pre-discharge exercise tests. FRISK Study Group. Eur Heart J (1997) 1.65
Relation between renal function, presentation, use of therapies and in-hospital complications in acute coronary syndrome: data from the SWEDEHEART register. J Intern Med (2009) 1.65
Inflammation and structural changes in the airways of patients with atopic and nonatopic asthma. BHR Group. Am J Respir Crit Care Med (2000) 1.58
Arginine-rich cationic proteins of human eosinophil granules: comparison of the constituents of eosinophilic and neutrophilic leukocytes. Lab Invest (1977) 1.57
Regulation of granulocyte function by hyaluronic acid. In vitro and in vivo effects on phagocytosis, locomotion, and metabolism. J Clin Invest (1980) 1.56
The role of interleukin-5, interleukin-8 and RANTES in the chemotactic attraction of eosinophils to the allergic lung. Clin Exp Allergy (1999) 1.55
Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation. Heart (2008) 1.54
Serum measurements of human neutrophil lipocalin (HNL) discriminate between acute bacterial and viral infections. Scand J Clin Lab Invest (1995) 1.51
Multicenter analytical evaluation of a high-sensitivity troponin T assay. Clin Chim Acta (2011) 1.49
The eosinophil granule proteins in serum, but not the oxidative metabolism of the blood eosinophils, are increased in cancer. Br J Haematol (1997) 1.47
Granulocytes and their secretory products, myeloperoxidase and eosinophil cationic protein, in bronchoalveolar lavage fluids from two lung lobes in normal subjects. Eur Respir J (1991) 1.45
Human neutrophil lipocalin is a unique marker of neutrophil inflammation in ulcerative colitis and proctitis. Gut (2002) 1.45
Eosinophil and neutrophil activity in asthma in a one-year trial with inhaled budesonide. The impact of smoking. Am J Respir Crit Care Med (1996) 1.44
Distinctive cationic proteins of the human eosinophil granule: major basic protein, eosinophil cationic protein, and eosinophil-derived neurotoxin. J Immunol (1983) 1.43
Surface characteristics of the U-937 human histiocytic lymphoma cell line: specific changes during inducible morphologic and functional differentiation in vitro. Haematol Blood Transfus (1981) 1.42
IL-5 priming of the PMA-induced oxidative metabolism of human eosinophils from allergic and normal subjects during a pollen season. Clin Exp Allergy (2001) 1.41
The combination of a continuous 12-lead ECG and troponin T; a valuable tool for risk stratification during the first 6 hours in patients with chest pain and a non-diagnostic ECG. Eur Heart J (2000) 1.40
Activation of B-lymphocytes during pollen season. Effect of immunotherapy. Clin Exp Allergy (1998) 1.40
The Gordon phenomenon induced by the eosinophil cationic protein and eosinophil protein X. J Allergy Clin Immunol (1982) 1.40
Eosinophil granule proteins in cardiopulmonary bypass with and without heparin coating. Ann Thorac Surg (1995) 1.40
Benefits of extended treatment with dalteparin in patients with unstable coronary artery disease eligible for revascularization. Eur Heart J (2002) 1.39
Continuous multilead ST-monitoring identifies patients with unstable coronary artery disease who benefit from extended antithrombotic treatment. Eur Heart J (2002) 1.39
Reduction of myocardial damage by prolonged treatment with subcutaneous low molecular weight heparin in unstable coronary artery disease. FRISC study group. Fragmin during Instability in Coronary Artery Disease. Eur Heart J (1999) 1.39
[Coronary vessel surgery. Are early operations really superior to the more and more effective drug therapy?]. Lakartidningen (1994) 1.39
The effect of a low molecular mass thrombin inhibitor, inogatran, and heparin on thrombin generation and fibrin turnover in patients with unstable coronary artery disease. Eur Heart J (1999) 1.39
Airway inflammation in smokers with nonobstructive and obstructive chronic bronchitis. Am Rev Respir Dis (1993) 1.39
Human eosinophil peroxidase: purification and characterization. J Immunol (1985) 1.36
Stimulation of degranulation from human eosinophils by platelet-activating factor. J Immunol (1989) 1.32
Inflammatory cells and eosinophilic activity in asthmatics investigated by bronchoalveolar lavage. The effects of antiasthmatic treatment with budesonide or terbutaline. Am Rev Respir Dis (1990) 1.31
Enhancement of factor XII dependent reactions by eosinophil cationic protein. Thromb Res (1979) 1.30
Cationic proteins of human granulocytes. IV. Esterase activity. Lab Invest (1975) 1.28
Serum myeloperoxidase and lactoferrin in neutropenia. Scand J Haematol (1977) 1.25
Kinetic studies of phagocytosis. I. The serum independent particle uptake by PMN from patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Rheum (1978) 1.24
Purification and characterization of a human neutrophil lipocalin (HNL) from the secondary granules of human neutrophils. Scand J Clin Lab Invest (1994) 1.23
Kinetic studies of phagocytosis of IgG-coated latex particles with a thrombocyte counter. J Lab Clin Med (1977) 1.22
The eosinophil component of the alveolitis in idiopathic pulmonary fibrosis. Signs of eosinophil activation in the lung are related to impaired lung function. Am Rev Respir Dis (1989) 1.21
Variations of blood eosinophils and eosinophil cationic protein in serum in patients with bronchial asthma. Studies during inhalation challenge test. Allergy (1978) 1.19
Neutrophil-associated activation markers in healthy smokers relates to a fall in DL(CO) and to emphysematous changes on high resolution CT. Respir Med (2001) 1.18
Indirect evidence of bronchial inflammation assessed by titration of inflammatory mediators in BAL fluid of patients with asthma. J Allergy Clin Immunol (1991) 1.17
Neutrophils from term and preterm newborn infants express the high affinity Fcgamma-receptor I (CD64) during bacterial infections. Pediatr Res (1999) 1.16
Myocardial damage, inflammation and thrombin inhibition in unstable coronary artery disease. Eur Heart J (2003) 1.16
The effect of immunotherapy on bronchial hyperresponsiveness and eosinophil cationic protein in pollen-allergic patients. J Allergy Clin Immunol (1988) 1.15
Radioimmunoassay of human eosinophil cationic protein (ECP) by an improved method. Establishment of normal levels in serum and turnover in vivo. Clin Exp Allergy (1991) 1.15
Cationic proteins of human granulocytes. VI. Effects on the complement system and mediation of chemotactic activity. J Immunol (1975) 1.15
Albumin, bradykinins, and eosinophil cationic protein on the nasal mucosal surface in patients with hay fever during natural allergen exposure. J Allergy Clin Immunol (1990) 1.14
IL-5 and TNF-alpha participate in recruitment of eosinophils to intestinal mucosa in ulcerative colitis. Dig Dis Sci (2001) 1.12
Plasma lipoproteins including high density lipoprotein subfractions during normal pregnancy. Obstet Gynecol (1985) 1.12
Neutrophil and eosinophil granulocytes in bacterial infection: sequential studies of cellular and serum levels of granule proteins. Br J Haematol (1978) 1.11
Studies on the phagocytic activity of the granulocytes in psoriasis and palmoplantar pustulosis. Br J Dermatol (1983) 1.11
Nasal and ocular symptoms, tear film stability and biomarkers in nasal lavage, in relation to building-dampness and building design in hospitals. Int Arch Occup Environ Health (1999) 1.10
Identification of IL-5 and RANTES as the major eosinophil chemoattractants in the asthmatic lung. J Allergy Clin Immunol (1996) 1.09
Myeloperoxidase in human lung lavage. I. A marker of local neutrophil activity. Inflammation (1990) 1.09
Effects of serum and cations on the selective release of granular proteins from human netrophils during phagocytosis. Scand J Haematol (1979) 1.08
Cationic proteins of human granulocytes. I. Isolation of the cationic proteins from the granules of leukaemic myeloid cells. Scand J Haematol (1972) 1.07
Effect of hyaluronic acid on phagocytosis of opsonized latex particles. Scand J Immunol (1980) 1.07
The role of the human neutrophil in the inflammatory reaction. Allergy (1980) 1.06
Piecemeal degranulation of peripheral blood eosinophils: a study of allergic subjects during and out of the pollen season. Am J Respir Cell Mol Biol (2000) 1.05
The development of an assay for human neutrophil lipocalin (HNL)--to be used as a specific marker of neutrophil activity in vivo and vitro. J Immunol Methods (1994) 1.05
Raised interleukin-10 is an indicator of poor outcome and enhanced systemic inflammation in patients with acute coronary syndrome. Heart (2007) 1.04
FRISC score for selection of patients for an early invasive treatment strategy in unstable coronary artery disease. Heart (2005) 1.04
Increased intraluminal release of eosinophil granule proteins EPO, ECP, EPX, and cytokines in ulcerative colitis and proctitis in segmental perfusion. Am J Gastroenterol (1999) 1.04
Blood eosinophil number and activity in relation to lung function in patients with asthma and with eosinophilia. J Allergy Clin Immunol (1991) 1.03
Kinetic studies of cell migration in a modified Boyden chamber: dependence on cell concentration and effects of the chymotrypsin-like cationic protein of human granulocytes. J Immunol (1979) 1.03
Human eosinophil cationic proteins (ECP and EPX) and their suppressive effects on lymphocyte proliferation. Immunobiology (1986) 1.03
The effect of eosinophils on collagen gel contraction and implications for tissue remodelling. Clin Exp Immunol (2004) 1.03
Analysis of fluid-phase mediators. Eur Respir J Suppl (2002) 1.02
Eosinophil cationic protein in inflammatory synovial effusions as evidence of eosinophil involvement. Ann Rheum Dis (1984) 1.01